ArticleFrontiers in pharmacology2026
The protective efficacy of baricitinib against lipopolysaccharide / D-Galactosamine-Induced acute liver Injury.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intorduction: Baricitinib (BARI), the selective JAK1/JAK2 inhibitor demonstrates enhanced immunological activity against several inflammatory conditions. Given the complex, multiple pathogeneses of acute liver inflammatory injury (ALIs), this study investigates BARI in a non-sterile murine model of fulminant hepatic failure to address existing management gaps. Methods: Mice were exposed to a toxic challenge with a single dose of lipopolysaccharide (LPS, 80 μg/kg, ip) and D-galactosamine (D-GaIN, 800 mg/kg, ip) on day 3. BARI (10 and 20 mg/kg, po) were administered prophylactically from day 1 to day 3 with the last dose of BARI given 2 h before LPS/D-GaIN. Results: Investigations revealed substantial lowering in liver function indices in BARI-treated groups after the pathogenic elevation in the LPS/D-GaIN group. These results coincided with remarkable reduction of necrosis and an improvement of hepatic architecture identified by the H&E staining in the BARI-treated groups compared to the disrupted histological features with substantial infiltration of inflammatory cells. The inflammatory cells observed in the LPS/ D-GaIN group represent a major source of ROS that contributes to nitrosative stress via the respiratory burst (NO), peroxidation of the PUFA of the cell membrane (MDA), and consumption of the cellular antioxidant molecules (TAC). This oxidative condition was reversed in BARI groups together with reestablishment of the antioxidant axis of Nrf2/HO-1 showing a remarkable capacity to restore redox equilibrium. The observed ameliorative potential of BARI is probably attributed to inhibition of IL-6 transcription, as confirmed by the inhibited activation of the transcription factor NF-κB, with subsequent inhibition of JAK2/STAT3. While curbing apoptosis as evidenced by reduced levels of cleaved caspase-3, BARI presented its ability to preserve the level of PI3K/AKT/ mTOR signaling. Conclusion: These findings highlight the protective capacity of BARI and its value for repurpose in medical management of acute liver failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.